<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17466" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Amlodipine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bulsara</surname>
            <given-names>Kishen G.</given-names>
          </name>
          <aff>Donald and Barbara Zucker School of Med</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cassagnol</surname>
            <given-names>Manouchkathe</given-names>
          </name>
          <aff>St. John's University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kishen Bulsara declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>4</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17466.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Amlodipine, an oral dihydropyridine calcium channel blocker, demonstrates prolonged efficacy by inhibiting voltage-dependent L-type calcium channels. This action&#x000a0;interrupts initial calcium influx, distinguishing it within its pharmacological class. With a half-life of 30 to 50 hours, amlodipine affords the convenience of once-daily dosing, contrasting with shorter-acting alternatives like nifedipine. Approved as amlodipine besylate by the United States Food and Drug Administration in 1987, this medication has since become a cornerstone in managing hypertension and related conditions. This&#x000a0;activity&#x000a0;discusses the indications, contraindications, and nuances of amlodipine therapy essential for interprofessional collaboration. By&#x000a0;also&#x000a0;discussing off-label uses, monitoring protocols, and pharmacokinetic intricacies, healthcare professionals can tailor treatment regimens to individual patient needs. Armed with a comprehensive understanding of amlodipine's pharmacology, healthcare providers are empowered to optimize therapeutic outcomes while mitigating adverse effects, thereby enhancing patient care and safety.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the United States Food and Drug Administration-approved and off-label indications of amlodipine.</p></list-item><list-item><p>Evaluate&#x000a0;the mechanism of action of amlodipine.</p></list-item><list-item><p>Assess&#x000a0;the adverse drug reactions of amlodipine.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from amlodipine pharmacotherapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17466&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17466">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17466.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Amlodipine is an oral dihydropyridine calcium channel blocker. The United States Food and Drug Administration (FDA) initially approved amlodipine besylate in 1987.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension:<bold>&#x000a0;</bold>Amlodipine is an excellent first-line choice among the multiple options of antihypertensive agents.&#x000a0;It may be used alone or in combination with other antihypertensive agents.<xref ref-type="bibr" rid="article-17466.r1">[1]</xref><xref ref-type="bibr" rid="article-17466.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Chronic stable angina: Amlodipine&#x000a0;is indicated for the symptomatic treatment of chronic stable angina. Amlodipine&#x000a0;may be used alone or in combination with other antianginal agents.<xref ref-type="bibr" rid="article-17466.r3">[3]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Vasospastic angina (Prinzmetal or variant angina): Amlodipine&#x000a0;is indicated to treat confirmed or suspected vasospastic angina.<xref ref-type="bibr" rid="article-17466.r4">[4]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Angiographically documented coronary artery disease: In patients with recently documented coronary artery disease by angiography and without heart failure or an ejection fraction &#x0003c;40%,&#x000a0;amlodipine&#x000a0;is indicated to reduce the risk of hospitalization&#x000a0;from angina and reduce the risk of a coronary revascularization procedure.<xref ref-type="bibr" rid="article-17466.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic nephropathy&#x000a0;<xref ref-type="bibr" rid="article-17466.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Left ventricular hypertrophy&#x000a0;<xref ref-type="bibr" rid="article-17466.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Raynaud phenomenon&#x000a0;<xref ref-type="bibr" rid="article-17466.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Silent myocardial ischemia&#x000a0;<xref ref-type="bibr" rid="article-17466.r9">[9]</xref><xref ref-type="bibr" rid="article-17466.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Group 1 pulmonary arterial hypertension: For patients with&#x000a0;idiopathic pulmonary artery hypertension and positive&#x000a0;vasodilator testing&#x000a0;<xref ref-type="bibr" rid="article-17466.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Microvascular angina:
<list list-type="bullet"><list-item><p>According to the 2023 American Heart Association/American College of Cardiology guideline for chronic coronary disease, amlodipine should be considered as a third-line therapy for microvascular angina (non-obstructive coronary artery disease and proven coronary microvascular dysfunction) in patients already on &#x003b2;-blockers.<xref ref-type="bibr" rid="article-17466.r12">[12]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Kidney transplant recipients:
<list list-type="bullet"><list-item><p>According to the Kidney Disease: Improving Global Outcomes "Management of Blood Pressure in Chronic Kidney Disease" guidelines, a dihydropyridine calcium channel blocker such as amlodipine or an angiotensin receptor blocker is recommended as the first-line antihypertensive agent in adult kidney transplant recipients.<xref ref-type="bibr" rid="article-17466.r13">[13]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17466.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Normally, vascular smooth muscle contraction&#x000a0;begins when calcium enters the cell via voltage-dependent L-type calcium channels. The calcium binds to&#x000a0;intracellular&#x000a0;calmodulin, which binds to and activates myosin light-chain kinase (MLCK). MLCK is responsible for the phosphorylation of the myosin light chain, ultimately leading to muscle contraction and vasoconstriction. Calcium-induced calcium release from the sarcoplasmic reticulum further amplifies the vascular smooth muscle contraction. This sequence of events&#x000a0;leads to a decreased vascular cross-sectional area, increased vascular resistance, and increased blood pressure.</p>
        <p>Amlodipine blocks the voltage-dependent L-type calcium channels, inhibiting the initial calcium influx. Reduced intracellular calcium causes decreased vascular smooth muscle contractility, increased smooth muscle relaxation, and resultant vasodilation. Additionally, amlodipine&#x000a0;is associated with improved vascular endothelial function in patients with hypertension. Amlodipine reduces blood pressure by inducing smooth muscle relaxation and vasodilatation.<xref ref-type="bibr" rid="article-17466.r3">[3]</xref></p>
        <p>Amlodipine's role in relieving stable angina involves the reduction of afterload secondary to its vasodilatory and antihypertensive properties. Reducing afterload lowers myocardial oxygen demand at any level of exertion, as the heart does not need to work as hard to pump blood into the systemic circulation. Amlodipine also alleviates Prinzmetal or variant angina by blocking coronary spasms and restoring blood flow in the coronary arteries.<xref ref-type="bibr" rid="article-17466.r14">[14]</xref></p>
        <p>Raynaud phenomenon is an excessive vascular response to cold temperature that manifests clinically by color changes of the distal skin of the digits and toes, nose, and earlobes. Amlodipine induces smooth muscle relaxation and is&#x000a0;an effective short-term treatment for patients with Raynaud phenomenon.<xref ref-type="bibr" rid="article-17466.r15">[15]</xref>&#x000a0;Angiotensin-converting enzyme inhibitors (ACE-Is)/angiotensin receptor blockers (ARBs) are the initial treatment of choice for diabetic nephropathy. However, clinical trials have shown that combined antihypertensive therapy with either amlodipine plus an ARBs/ACE-Is exerts a greater antiproteinuric effect in patients with type 2 diabetic nephropathy.<xref ref-type="bibr" rid="article-17466.r16">[16]</xref><xref ref-type="bibr" rid="article-17466.r17">[17]</xref>&#x000a0;ASCOT (Anglo-Scandinavian Outcome Trial)&#x000a0;demonstrated that&#x000a0;an amlodipine-based blood pressure regimen&#x000a0;decreased the long-term incidence of stroke compared with atenolol, but further research is still required.<xref ref-type="bibr" rid="article-17466.r18">[18]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> The absolute bioavailability of amlodipine is between 64% and 90%. Food&#x000a0;does not alter the bioavailability of amlodipine. Peak plasma concentrations are achieved between 6 and 12 hours. Steady-state plasma levels are achieved after 7 to 8 days of daily dosing of amlodipine. Patients with hepatic dysfunction have decreased clearance of amlodipine. Accordingly, there is an increase in area under the curve of approximately 40% to 60% in patients with liver conditions.</p>
        <p><bold>Distribution:</bold> Amlodipine has high plasma protein binding (93%).</p>
        <p><bold>Metabolism:</bold> Amlodipine is extensively metabolized by the liver to inactive metabolites. Cytochrome P-450 (CYP) CYP3A4 and CYP3A5 play an important role in the metabolism of amlodipine.<xref ref-type="bibr" rid="article-17466.r19">[19]</xref><xref ref-type="bibr" rid="article-17466.r20">[20]</xref><xref ref-type="bibr" rid="article-17466.r21">[21]</xref></p>
        <p><bold>Excretion:</bold>&#x000a0;Amlodipine's plasma half-life is biphasic, with a terminal elimination half-life of about 30 to 50 hours, which is increased with hepatic dysfunction. Amlodipine is primarily excreted renally; 10% of the parent compound and 60% of the metabolites are excreted in the urine.</p>
      </sec>
      <sec id="article-17466.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths </bold>
</p>
        <p>Amlodipine is primarily administered orally and is available in 2.5, 5, and 10 mg tablets. Additionally, suspensions created from oral tablets are available for pediatric and&#x000a0;older patients with difficulty swallowing.&#x000a0;Compared to nifedipine and other medications in the dihydropyridine class, amlodipine has the longest half-life at 30 to 50 hours. The benefit of such a long half-life is having once-daily dosing.<xref ref-type="bibr" rid="article-17466.r22">[22]</xref></p>
        <p>
<bold>Recommended Dosages</bold>
</p>
        <p>
<bold>Hypertension</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults: Initial dose of 5 mg; maximum dose of 10 mg daily</p>
          </list-item>
          <list-item>
            <p>Older&#x000a0;and debilitated patients: Reduce initial dose to 2.5 mg; maximum dose of 10 mg daily</p>
          </list-item>
          <list-item>
            <p>Adolescents and children aged 6 or older: 2.5 to 5 mg once daily; maximum dose of 5 mg daily</p>
          </list-item>
          <list-item>
            <p>Children aged 6 or younger: 0.05 to 0.2 mg/kg/d; maximum dose 0.3 to 0.6 mg/kg/d (up to 5 mg/d)&#x000a0;<xref ref-type="bibr" rid="article-17466.r23">[23]</xref></p>
          </list-item>
        </list>
        <p>
<bold>CAD, Chronic Stable Angina, Prinzmental Angina, CAD Documented by Angiography and Without Heart Failure or Ejection Fraction Less than 40%</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults: The initial dose is 5 to 10 mg once daily.</p>
          </list-item>
          <list-item>
            <p>Older and debilitated patients: The initial dose is 5 mg once daily; the maintenance dose is 10 mg once daily.<xref ref-type="bibr" rid="article-17466.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>Amlodipine can be used as&#x000a0;monotherapy or in combination with several different medications to manage hypertension or coronary artery disease. Common combinations include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Amlodipine/atorvastatin:&#x000a0;Atorvastatin is a lipid-lowering agent that blocks cholesterol synthesis and is administered to reduce cardiovascular events.<xref ref-type="bibr" rid="article-17466.r24">[24]</xref><xref ref-type="bibr" rid="article-17466.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Amlodipine/aliskiren or amlodipine/aliskiren/hydrochlorothiazide:&#x000a0;Aliskiren is a direct renin inhibitor that binds renin and prevents activating the renin-angiotensin-aldosterone system (RAAS). Hydrochlorothiazide is a thiazide diuretic that leads to a reduction in blood volume. Both combinations lower blood pressure.<xref ref-type="bibr" rid="article-17466.r26">[26]</xref><xref ref-type="bibr" rid="article-17466.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Amlodipine/benazepril or amlodipine/perindopril:&#x000a0;Benazepril and perindopril are angiotensin-coveting enzyme inhibitors that block the conversion of angiotensin I to angiotensin II in the RAAS.<xref ref-type="bibr" rid="article-17466.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Amlodipine/olmesartan or amlodipine/telmisartan or amlodipine/valsartan:&#x000a0;Olmesartan, telmisartan, and valsartan are angiotensin II receptor blockers (ARBs) that inhibit the activity of angiotensin II in the RAAS.<xref ref-type="bibr" rid="article-17466.r29">[29]</xref><xref ref-type="bibr" rid="article-17466.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Amlodipine/valsartan/hydrochlorothiazide:&#x000a0;A randomized controlled trial demonstrated the efficacy of triple therapy (amlodipine/valsartan/hydrochlorothiazide) for moderate or severe hypertension.<xref ref-type="bibr" rid="article-17466.r31">[31]</xref><xref ref-type="bibr" rid="article-17466.r32">[32]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Amlodipine is primarily metabolized by the liver, and the plasma elimination half-life is prolonged with&#x000a0;impaired hepatic function; gradual titration of the dose is recommended. The initial&#x000a0;dose is 2.5 mg once daily for hypertension or 5 mg once daily for angina. Adjust the dosage based on clinical response.<xref ref-type="bibr" rid="article-17466.r2">[2]</xref></p>
        <p><bold>Renal impairment:</bold> Renal impairment does not significantly influence the pharmacokinetics of amlodipine. Consequently, patients with renal&#x000a0;impairment&#x000a0;do not&#x000a0;require dose adjustment.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Untreated hypertension in pregnancy increases the risk of preeclampsia, premature delivery, intrauterine growth restriction, and intrauterine death.&#x000a0;Chronic Hypertension and Pregnancy results indicate that in&#x000a0;pregnant women with mild chronic hypertension, an approach of target blood pressure of less than 140/90 mm Hg was associated with better pregnancy outcomes than a strategy of reserving treatment only for severe hypertension.<xref ref-type="bibr" rid="article-17466.r33">[33]</xref> Based on these findings, the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine guidelines suggest&#x000a0;treatment with antihypertensive agents for mild chronic hypertension in pregnancy to a goal BP of less than 140/90 mm Hg.<xref ref-type="bibr" rid="article-17466.r34">[34]</xref>&#x000a0;Calcium channel blockers are widely used in pregnancy, and ACOG suggests other agents such as labetalol, nifedipine, and methyldopa.<xref ref-type="bibr" rid="article-17466.r35">[35]</xref>&#x000a0;However, amlodipine exposure in pregnancy does not appear to be associated with increased fetal malformations compared with other antihypertensive medications or maternal hypertension without treatment.<xref ref-type="bibr" rid="article-17466.r36">[36]</xref>&#x000a0;Based on a recent meta-analysis, amlodipine can also be used&#x000a0;safely for hypertension during pregnancy.<xref ref-type="bibr" rid="article-17466.r37">[37]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Human milk levels of amlodipine are low, and plasma levels in breastfed infants are undetectable. Maternal use of amlodipine during breastfeeding has not caused any adverse effects in breastfed infants. Amlodipine is acceptable in nursing mothers.<xref ref-type="bibr" rid="article-17466.r36">[36]</xref><xref ref-type="bibr" rid="article-17466.r38">[38]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;The efficacy and safety of amlodipine in children&#x000a0;younger than 6 years old remain uncertain. Per the guidelines from the American Heart Association and American Thoracic Society for pediatric pulmonary hypertension, amlodipine doses should always&#x000a0;be titrated up from a lower dose. A trial of amlodipine should be performed only in those patients who have positive acute vasoreactivity testing with nitric oxide or epoprostenol. In children with a previous history of high-altitude pulmonary edema (HAPE), amlodipine may be deemed a reasonable option for prophylaxis.<xref ref-type="bibr" rid="article-17466.r39">[39]</xref></p>
        <p><bold>Older patients</bold>: When prescribing amlodipine for older individuals, it's advisable to exercise caution, typically initiating treatment at the lower end of the dosage spectrum. This approach acknowledges the higher likelihood of impaired hepatic or cardiac function, as well as the increased incidence of accompanying diseases or concurrent medication usage. Older patients may have decreased clearance, leading to increased area under the curve, necessitating a lower initial dose.<xref ref-type="bibr" rid="article-17466.r2">[2]</xref></p>
      </sec>
      <sec id="article-17466.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The significant adverse effects of amlodipine include peripheral edema, heart failure, pulmonary edema, flushing, dizziness, headache, drowsiness, skin rash, nausea, abdominal pain, and constipation. Researchers observed edema, dizziness, flushing, and palpitations in controlled clinical trials in a dose-dependent manner. For example, at a dose of 10 mg, the incidence of edema, dizziness, flushing, and palpitations was 10.8%, 3.4%, 2.6%, and 4.5%, respectively. The incidence of headaches, fatigue, nausea, and abdominal pain was 7.3%, 4.5%, 2.9%, and 1.6%, respectively.<xref ref-type="bibr" rid="article-17466.r40">[40]</xref>&#x000a0;</p>
        <p>Calcium channel blockers, including amlodipine, have been linked to rare instances of idiosyncratic drug-induced liver disease. A mixed&#x000a0;hepatocellular-cholestatic pattern is typical of amlodipine-induced liver injury.<xref ref-type="bibr" rid="article-17466.r41">[41]</xref>&#x000a0;Patients have complete recovery&#x000a0;4 to 8 weeks after stopping the drug.<xref ref-type="bibr" rid="article-17466.r42">[42]</xref>&#x000a0;Amlodipine-induced gingival hyperplasia is a common adverse effect. Maintaining good oral hygiene practices is beneficial for prevention. In cases where gingival hyperplasia persists despite these measures, surgical intervention may be necessary.<xref ref-type="bibr" rid="article-17466.r43">[43]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Coadministration of amlodipine and clarithromycin or erythromycin has reportedly increased the risk of hypotension and acute kidney injury due to decreased metabolism by CYP3A4.<xref ref-type="bibr" rid="article-17466.r44">[44]</xref>&#x000a0;Additionally, when amlodipine is used with high doses of statins, there is an increased risk for myopathy&#x000a0;and rhabdomyolysis.<xref ref-type="bibr" rid="article-17466.r45">[45]</xref>&#x000a0;The interaction with&#x000a0;tacrolimus is described in the monitoring section.</p>
        <p>
<bold>Prescribing Cascade</bold>
</p>
        <p>It is important to note that amlodipine can cause peripheral edema. A prescribing cascade occurs when the edema is mistaken as a new medical condition, and a diuretic is consequently prescribed to treat the edema.<xref ref-type="bibr" rid="article-17466.r46">[46]</xref></p>
      </sec>
      <sec id="article-17466.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Amlodipine is contraindicated in patients with known hypersensitivity to amlodipine or its dosage form components. Lymphocyte transformation test can be used to diagnose drug allergy.<xref ref-type="bibr" rid="article-17466.r47">[47]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p>Amlodipine is contraindicated in patients with cardiogenic shock, severe aortic stenosis, unstable angina, severe hypotension, heart failure, and hepatic impairment.&#x000a0;According to the manufacturer's labeling, patients with severe coronary artery disease may have worsening angina after initiating amlodipine therapy.&#x000a0;In cardiogenic shock, the heart cannot pump effectively, exacerbated by inhibiting the influx of calcium ions into cardiac cells. In severe aortic stenosis, amlodipine can cause ventricular collapse and dysfunction. Amlodipine causes a reflexive increase in cardiac contractility in unstable angina, increasing myocardial oxygen demand and worsening ischemia. Amlodipine can further&#x000a0;reduce blood pressure, causing hypoperfusion to vital organs and syncope in patients with severe hypotension.<xref ref-type="bibr" rid="article-17466.r48">[48]</xref>&#x000a0;Patients with heart failure may experience pulmonary edema, shortness of breath, and&#x000a0;dyspnea with amlodipine.<xref ref-type="bibr" rid="article-17466.r49">[49]</xref>&#x000a0;Patients with hepatic impairment may not metabolize amlodipine effectively, leading to a longer half-life with possible increases in plasma concentrations.<xref ref-type="bibr" rid="article-17466.r50">[50]</xref></p>
      </sec>
      <sec id="article-17466.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>In general, laboratory monitoring is not necessary for patients taking amlodipine. Since amlodipine is an antihypertensive medication, clinicians and patients should regularly measure blood pressure to achieve target levels per the 2017 American College of Cardiology/American Heart Association hypertension guidelines. Furthermore, the healthcare team should monitor patients for adverse effects such as peripheral edema, dizziness, and flushing.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="26102977">[51]</ext-link>&#x000a0;Amlodipine may increase the AUC of tacrolimus. In one study, amlodipine decreased the tacrolimus clearance by 2.2 to 3.8-fold, increasing the area under the curve and systemic exposure in CYP3A5 expressers. Monitoring of trough blood levels of tacrolimus is recommended.<xref ref-type="bibr" rid="article-17466.r51">[52]</xref></p>
      </sec>
      <sec id="article-17466.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Amlodipine overdose and toxicity can lead to massive vasodilation, hypotension, and&#x000a0;reflex&#x000a0;tachycardia&#x000a0;as compensatory mechanisms.&#x000a0;Prolonged systemic hypotension can progress to shock and even death.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Activated charcoal should be administered to patients with amlodipine&#x000a0;overdose.&#x000a0;The hypotension usually remits intravenous (IV) fluid resuscitation, IV calcium gluconate, and vasopressor therapy with norepinephrine or dopamine. High-dose insulin is also sometimes administered as research has shown it lowers mortality and improves hemodynamics. Electrocardiographic results, vital signs, kidney function, urine output, and electrolytes require continual monitoring during an overdose.<xref ref-type="bibr" rid="article-17466.r48">[48]</xref><xref ref-type="bibr" rid="article-17466.r52">[53]</xref>&#x000a0;As amlodipine has high plasma protein binding, hemodialysis is not likely to be beneficial. A recent case report describes successful resin hemadsorption/hemoperfusion treatment for&#x000a0;amlodipine overdose,&#x000a0;demonstrating its efficacy in resolving severe toxicity and hemodynamic instability.<xref ref-type="bibr" rid="article-17466.r53">[54]</xref></p>
      </sec>
      <sec id="article-17466.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Amlodipine is a first-line choice among the myriad options of antihypertensive agents. Amlodipine has also shown robust reductions in cardiovascular endpoints (especially stroke). In addition, compared to nifedipine and other medications in the&#x000a0;dihydropyridine&#x000a0;class, amlodipine has the longest half-life at 30 to 50 hours. The benefit of such a long half-life is having&#x000a0;once-daily dosing. Therefore, healthcare providers, including physicians, nurse practitioners, physician assistants, and pharmacists, should be familiar with the indications and contraindications of amlodipine. However, the drug can cause severe hypotension in overdose; it is recommended to titrate the dose with an initial low dose gradually. In addition, long-term patient monitoring is necessary for optimal blood pressure control. The PERSONAL-CovidBP trial&#x000a0;demonstrated&#x000a0;that smartphone-enabled remote precision dosing of amlodipine effectively lowered blood pressure in individuals with primary hypertension during the COVID-19 pandemic.<xref ref-type="bibr" rid="article-17466.r54">[55]</xref></p>
        <p>Amlodipine therapy requires the participation of the entire interprofessional healthcare team. Clinicians and specialists will typically initiate treatment. The pharmacist should&#x000a0;report to the clinician for potential drug interactions (eg, simvastatin or erythromycin). In addition, pharmacists should verify dosing and educate the patient about the common adverse drug reactions. The nurse should assess patient adherence and offer to counsel on medication administration. Both nursing and pharmacy staff should alert the prescriber if they encounter any issues. In an acute overdose of amlodipine, emergency physicians and triage nurses should stabilize the patient with a primary focus on circulation. In a massive overdose of amlodipine, it is important to obtain an emergency consultation with a medical toxicologist. Critical care physician supervision is necessary for patients requiring vasopressor therapy in medical intensive care units. The interprofessional&#x000a0;team approach can improve patient outcomes related to amlodipine therapy by maximizing efficacy and minimizing the risk of adverse drug reactions. In addition, a pragmatic randomized controlled trial indicated that team-based care involving community pharmacists and nurses working in an interprofessional manner with clinicians could accomplish long-term blood pressure control related to antihypertensive therapy, including calcium channel blockers.<xref ref-type="bibr" rid="article-17466.r55">[56]</xref></p>
      </sec>
      <sec id="article-17466.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17466&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17466">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17466/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17466">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17466.s11">
        <title>References</title>
        <ref id="article-17466.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCormack</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>O'Flynn</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Management of hypertension in adults in primary care: NICE guideline.</article-title>
            <source>Br J Gen Pract</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>62</volume>
            <issue>596</issue>
            <fpage>163</fpage>
            <page-range>163-4</page-range>
            <pub-id pub-id-type="pmid">22429432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fares</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>DiNicolantonio</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>O'Keefe</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lavie</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes.</article-title>
            <source>Open Heart</source>
            <year>2016</year>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>e000473</fpage>
            <pub-id pub-id-type="pmid">27752334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pavasini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Camici</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Crea</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Danchin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manolis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marzilli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
              <name>
                <surname>Lopez-Sendon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment.</article-title>
            <source>Eur Heart J</source>
            <year>2019</year>
            <month>Jan</month>
            <day>07</day>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-194</page-range>
            <pub-id pub-id-type="pmid">30165445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fihn</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Gardin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berra</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blankenship</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Dallas</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Foody</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Hinderliter</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Kligfield</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Munger</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Prager</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Sabik</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Sikkema</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spertus</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force</collab>
            </person-group>
            <article-title>2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.</article-title>
            <source>Circulation</source>
            <year>2012</year>
            <month>Dec</month>
            <day>18</day>
            <volume>126</volume>
            <issue>25</issue>
            <fpage>e354</fpage>
            <page-range>e354-471</page-range>
            <pub-id pub-id-type="pmid">23166211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Byington</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Furberg</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Hunninghake</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators.</article-title>
            <source>Circulation</source>
            <year>2000</year>
            <month>Sep</month>
            <day>26</day>
            <volume>102</volume>
            <issue>13</issue>
            <fpage>1503</fpage>
            <page-range>1503-10</page-range>
            <pub-id pub-id-type="pmid">11004140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tabur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O&#x0011f;uz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sabuncu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Korkmaz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>&#x000c7;elik</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus.</article-title>
            <source>Clin Exp Hypertens</source>
            <year>2015</year>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>177</fpage>
            <page-range>177-83</page-range>
            <pub-id pub-id-type="pmid">25050869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ostroumova</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>Kochetkov</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>[Effects of Amlodipine/Lisinopril Fixed-Dose Combination on Severity of Left Ventricular Hypertrophy and Parameters of Myocardial Stiffness in Patients With Hypertension].</article-title>
            <source>Kardiologiia</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>56</volume>
            <issue>11</issue>
            <fpage>27</fpage>
            <page-range>27-37</page-range>
            <pub-id pub-id-type="pmid">28290816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Giles</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>658</fpage>
            <page-range>658-64</page-range>
            <pub-id pub-id-type="pmid">24352340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perna</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cianfrone</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Luca</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Amico</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Coli</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Amlodipine in ischaemic left ventricular dysfunction with mild to moderate heart failure.</article-title>
            <source>Clin Drug Investig</source>
            <year>1998</year>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>289</fpage>
            <page-range>289-96</page-range>
            <pub-id pub-id-type="pmid">18370550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leonard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Near-complete migraine prophylaxis with amlodipine: a case report.</article-title>
            <source>J Pain Symptom Manage</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>571</fpage>
            <page-range>571-3</page-range>
            <pub-id pub-id-type="pmid">18053876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velayati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valerio</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tariq</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lanier</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Update on pulmonary arterial hypertension pharmacotherapy.</article-title>
            <source>Postgrad Med</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>128</volume>
            <issue>5</issue>
            <fpage>460</fpage>
            <page-range>460-73</page-range>
            <pub-id pub-id-type="pmid">27232660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Writing Committee Members</collab>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Bittner</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Demeter</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Fearon</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kazi</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kolte</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kumbhani</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>LoFaso</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mahtta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mark</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Minissian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navar</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Piano</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Talbot</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Taqueti</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>van Diepen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wiggins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic&#x000a0;Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2023</year>
            <month>Aug</month>
            <day>29</day>
            <volume>82</volume>
            <issue>9</issue>
            <fpage>833</fpage>
            <page-range>833-955</page-range>
            <pub-id pub-id-type="pmid">37480922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <collab>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group</collab>
            <article-title>KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney&#x000a0;Disease.</article-title>
            <source>Kidney Int</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>99</volume>
            <issue>3S</issue>
            <fpage>S1</fpage>
            <page-range>S1-S87</page-range>
            <pub-id pub-id-type="pmid">33637192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gamal El-Din</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Pryde</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Scheuer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Catterall</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Structural basis for inhibition of a voltage-gated Ca<sup>2+</sup> channel by Ca<sup>2+</sup> antagonist drugs.</article-title>
            <source>Nature</source>
            <year>2016</year>
            <month>Sep</month>
            <day>01</day>
            <volume>537</volume>
            <issue>7618</issue>
            <fpage>117</fpage>
            <page-range>117-121</page-range>
            <pub-id pub-id-type="pmid">27556947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pope</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Raynaud's phenomenon (primary).</article-title>
            <source>BMJ Clin Evid</source>
            <year>2013</year>
            <month>Oct</month>
            <day>10</day>
            <volume>2013</volume>
            <fpage>1119</fpage>
            <pub-id pub-id-type="pmid">24112969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hunsicker</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Berl</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pohl</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ritz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Rohde</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raz</surname>
                <given-names>I</given-names>
              </name>
              <collab>Collaborative Study Group</collab>
            </person-group>
            <article-title>Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Sep</month>
            <day>20</day>
            <volume>345</volume>
            <issue>12</issue>
            <fpage>851</fpage>
            <page-range>851-60</page-range>
            <pub-id pub-id-type="pmid">11565517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuriyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tomonari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tokudome</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Horiguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hosoya</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.</article-title>
            <source>Hypertens Res</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>849</fpage>
            <page-range>849-55</page-range>
            <pub-id pub-id-type="pmid">12484508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whiteley</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Godec</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rostamian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whitehouse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mackay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Incidence of Stroke and Dementia in ASCOT.</article-title>
            <source>Stroke</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>52</volume>
            <issue>10</issue>
            <fpage>3088</fpage>
            <page-range>3088-3096</page-range>
            <pub-id pub-id-type="pmid">34192893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>245</fpage>
            <page-range>245-9</page-range>
            <pub-id pub-id-type="pmid">24301608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cataldi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Celentano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bencivenga</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Arcopinto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Resnati</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Manes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dodani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Comnes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vander Stichele</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rengo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Giallauria</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Trama</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cittadini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taglialatela</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Identification of Drugs Acting as Perpetrators in Common Drug Interactions in a Cohort of Geriatric Patients from Southern Italy and Analysis of the Gene Polymorphisms That Affect Their Interacting Potential.</article-title>
            <source>Geriatrics (Basel)</source>
            <year>2023</year>
            <month>Aug</month>
            <day>24</day>
            <volume>8</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">37736884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Association of <italic>CYP3A5</italic> Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential Hypertension.</article-title>
            <source>Pharmgenomics Pers Med</source>
            <year>2021</year>
            <volume>14</volume>
            <fpage>189</fpage>
            <page-range>189-197</page-range>
            <pub-id pub-id-type="pmid">33564260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Zwieten</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties.</article-title>
            <source>Clin Cardiol</source>
            <year>1994</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9 Suppl 3</issue>
            <fpage>III3</fpage>
            <page-range>III3-6</page-range>
            <pub-id pub-id-type="pmid">9156957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Charchar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Prabhakaran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schlaich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stergiou</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wainford</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schutte</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>2020 International Society of Hypertension Global Hypertension Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>1334</fpage>
            <page-range>1334-1357</page-range>
            <pub-id pub-id-type="pmid">32370572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Athyros</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Katsiki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Karagiannis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>7</issue>
            <fpage>791</fpage>
            <page-range>791-2</page-range>
            <pub-id pub-id-type="pmid">23672630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curran</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.</article-title>
            <source>Drugs</source>
            <year>2010</year>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>191</fpage>
            <page-range>191-213</page-range>
            <pub-id pub-id-type="pmid">20108992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teo</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mancia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dagenais</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dans</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Copland</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pogue</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <collab>Aliskiren Prevention of Later Life Outcomes trial Investigators</collab>
            </person-group>
            <article-title>Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial.</article-title>
            <source>Eur Heart J</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>26</issue>
            <fpage>1743</fpage>
            <page-range>1743-51</page-range>
            <pub-id pub-id-type="pmid">24616335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zion</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Izzo</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results.</article-title>
            <source>Expert Rev Cardiovasc Ther</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>421</fpage>
            <page-range>421-7</page-range>
            <pub-id pub-id-type="pmid">21417713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brook</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Kaciroti</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dahl&#x000f6;f</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Velazquez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zappe</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Hau</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2018</year>
            <month>Jan</month>
            <day>04</day>
            <volume>7</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">29301757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruilope</surname>
                <given-names>LM</given-names>
              </name>
              <collab>SEVITENSION Study Investigators</collab>
            </person-group>
            <article-title>Fixed-Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>528</fpage>
            <page-range>528-35</page-range>
            <pub-id pub-id-type="pmid">26395174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Leu</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: A double-blind, randomized trial.</article-title>
            <source>J Chin Med Assoc</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>83</volume>
            <issue>10</issue>
            <fpage>900</fpage>
            <page-range>900-905</page-range>
            <pub-id pub-id-type="pmid">33009241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Asayama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Maestre</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Staessen</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Starting Antihypertensive Drug Treatment With Combination Therapy: Controversies in Hypertension - Con Side of the Argument.</article-title>
            <source>Hypertension</source>
            <year>2021</year>
            <month>Mar</month>
            <day>03</day>
            <volume>77</volume>
            <issue>3</issue>
            <fpage>788</fpage>
            <page-range>788-798</page-range>
            <pub-id pub-id-type="pmid">33566687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calhoun</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lacourci&#x000e8;re</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Glazer</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.</article-title>
            <source>Hypertension</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-9</page-range>
            <pub-id pub-id-type="pmid">19470877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tita</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Szychowski</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Boggess</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dugoff</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sibai</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aagaard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Plante</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Metz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Esplin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saade</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Foroutan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tuuli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Simhan</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Palatnik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>August</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>Kinzler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Krishna</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Norton</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Skupski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>El-Sayed</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Ogunyemi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Galis</surname>
                <given-names>ZS</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ambalavanan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cutter</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>WW</given-names>
              </name>
              <collab>Chronic Hypertension and Pregnancy (CHAP) Trial Consortium</collab>
            </person-group>
            <article-title>Treatment for Mild Chronic Hypertension during Pregnancy.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>May</month>
            <day>12</day>
            <volume>386</volume>
            <issue>19</issue>
            <fpage>1781</fpage>
            <page-range>1781-1792</page-range>
            <pub-id pub-id-type="pmid">35363951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <collab>Society for Maternal-Fetal Medicine; Publications Committee. Electronic address: pubs@smfm.org</collab>
            <article-title>Society for Maternal-Fetal Medicine Statement:&#x000a0;Antihypertensive therapy for&#x000a0;mild&#x000a0;chronic hypertension in pregnancy-The&#x000a0;Chronic Hypertension and&#x000a0;Pregnancy trial.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>227</volume>
            <issue>2</issue>
            <fpage>B24</fpage>
            <page-range>B24-B27</page-range>
            <pub-id pub-id-type="pmid">35710594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>e26</fpage>
            <page-range>e26-e50</page-range>
            <pub-id pub-id-type="pmid">30575676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malha</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>August</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Safety of Antihypertensive Medications in Pregnancy: Living With Uncertainty.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2019</year>
            <month>Aug</month>
            <day>06</day>
            <volume>8</volume>
            <issue>15</issue>
            <fpage>e013495</fpage>
            <pub-id pub-id-type="pmid">31345085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mei</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis.</article-title>
            <source>Arch Gynecol Obstet</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>306</volume>
            <issue>6</issue>
            <fpage>1891</fpage>
            <page-range>1891-1900</page-range>
            <pub-id pub-id-type="pmid">35305140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r38">
          <label>38</label>
          <element-citation publication-type="book">
            <chapter-title>Amlodipine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>6</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">29999724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abman</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Hansmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Archer</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Ivy</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Adatia</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Rosenzweig</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Raj</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Cornfield</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stenmark</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Steinhorn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Th&#x000e9;baud</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fineman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kuehne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Feinstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Friedberg</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Earing</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Kinsella</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Mullen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Deterding</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kulik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mallory</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Humpl</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wessel</surname>
                <given-names>DL</given-names>
              </name>
              <collab>American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society</collab>
            </person-group>
            <article-title>Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>Nov</month>
            <day>24</day>
            <volume>132</volume>
            <issue>21</issue>
            <fpage>2037</fpage>
            <page-range>2037-99</page-range>
            <pub-id pub-id-type="pmid">26534956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vukadinovi&#x00107;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Scholz</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Messerli</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mahfoud</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials.</article-title>
            <source>J Hypertens</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>2093</fpage>
            <page-range>2093-2103</page-range>
            <pub-id pub-id-type="pmid">31107359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r41">
          <label>41</label>
          <element-citation publication-type="book">
            <chapter-title>Calcium Channel Blockers</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">31643892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r42">
          <label>42</label>
          <element-citation publication-type="book">
            <chapter-title>Amlodipine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2016</year>
            <month>3</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">31643900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okumu&#x0015f;</surname>
                <given-names>&#x000d6;F</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Gingival Growth Due to Amlodipine Use With a 445-nm Diode Laser: A Case Report.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>12</issue>
            <fpage>e32592</fpage>
            <pub-id pub-id-type="pmid">36660514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gandhi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fleet</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wald</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>AX</given-names>
              </name>
            </person-group>
            <article-title>Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury.</article-title>
            <source>JAMA</source>
            <year>2013</year>
            <month>Dec</month>
            <day>18</day>
            <volume>310</volume>
            <issue>23</issue>
            <fpage>2544</fpage>
            <page-range>2544-53</page-range>
            <pub-id pub-id-type="pmid">24346990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siriangkhawut</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tansakul</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Uchaipichat</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction.</article-title>
            <source>Saudi Pharm J</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>823</fpage>
            <page-range>823-829</page-range>
            <pub-id pub-id-type="pmid">28951665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savage</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Visentin</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Bronskill</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gruneir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giannakeas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Luke</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Stall</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rochon</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a Common Prescribing Cascade of Calcium Channel Blockers and Diuretics in Older Adults With Hypertension.</article-title>
            <source>JAMA Intern Med</source>
            <year>2020</year>
            <month>May</month>
            <day>01</day>
            <volume>180</volume>
            <issue>5</issue>
            <fpage>643</fpage>
            <page-range>643-651</page-range>
            <pub-id pub-id-type="pmid">32091538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monge-Ortega</surname>
                <given-names>OP</given-names>
              </name>
              <name>
                <surname>Dom&#x000ed;nguez-Ortega</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Mu&#x000f1;oz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caba&#x000f1;as</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lluch-Bernal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fiandor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bravo-Gallego</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Quirce</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Delayed allergic reaction to amlodipine with a positive lymphocyte transformation test].</article-title>
            <source>Rev Alerg Mex</source>
            <year>2017</year>
            <season>Oct-Dec</season>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>505</fpage>
            <page-range>505-508</page-range>
            <pub-id pub-id-type="pmid">29249113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Flatt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khouzam</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>The potential detrimental effects of calcium channel blockers' overdose and current available management.</article-title>
            <source>Ann Transl Med</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <pub-id pub-id-type="pmid">29404362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Vries</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Dunselman</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines.</article-title>
            <source>Am Heart J</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>139</volume>
            <issue>2 Pt 1</issue>
            <fpage>185</fpage>
            <page-range>185-94</page-range>
            <pub-id pub-id-type="pmid">10650289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abernethy</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of calcium antagonists under development.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1988</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-14</page-range>
            <pub-id pub-id-type="pmid">3042243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zuo</surname>
                <given-names>XC</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>YN</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>ZN</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ouyang</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine.</article-title>
            <source>Drug Metab Pharmacokinet</source>
            <year>2013</year>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>398</fpage>
            <page-range>398-405</page-range>
            <pub-id pub-id-type="pmid">23438946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St-Onge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dub&#x000e9;</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guimont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Godwin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Archambault</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Chauny</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Frenette</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Darveau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Sage</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Poitras</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Provencher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Juurlink</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Blais</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Treatment for calcium channel blocker poisoning: a systematic review.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>926</fpage>
            <page-range>926-44</page-range>
            <pub-id pub-id-type="pmid">25283255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Omar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Parris</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gurke</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Hemoadsorption Therapy for Calcium Channel Blocker Overdose: A Case Report.</article-title>
            <source>J Emerg Med</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>66</volume>
            <issue>4</issue>
            <fpage>e463</fpage>
            <page-range>e463-e466</page-range>
            <pub-id pub-id-type="pmid">38461133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collier</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Godec</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shiel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chowdury</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ebano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Monk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pheby</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pheby</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Foubister</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Saxena</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Siddle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Timlin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Goldsmith</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Deeming</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Gabe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McManus</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Caulfield</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Personalized Antihypertensive Treatment Optimization With Smartphone-Enabled Remote Precision Dosing of Amlodipine During the COVID-19 Pandemic (PERSONAL-CovidBP Trial).</article-title>
            <source>J Am Heart Assoc</source>
            <year>2024</year>
            <month>Feb</month>
            <day>20</day>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>e030749</fpage>
            <pub-id pub-id-type="pmid">38323513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17466.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santschi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wuerzner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pais</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chiolero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schaller</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cloutier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Paradis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Burnier</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Team-Based Care for Improving Hypertension Management: A Pragmatic Randomized Controlled Trial.</article-title>
            <source>Front Cardiovasc Med</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>760662</fpage>
            <pub-id pub-id-type="pmid">34760950</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
